EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of a high-throughput TR-FRET screening assay for LAG-3/FGL1 interaction

Somaya A Abdel-Rahman, Longfei Zhang, Moustafa T Gabr

SLAS Discovery · 2023

DOI: 10.1016/j.slasd.2023.04.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SLAS Discovery, 2023. Verfasst von Somaya A Abdel-Rahman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, NY 10065, USA; Department of Medicinal Chem…. Hauptthemen laut MEDLINE: Fluorescence Resonance Energy Transfer, High-Throughput Screening Assays. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lymphocyte activation gene 3 (LAG-3) is a negative immune checkpoint and a key regulator of immune homeostasis with multiple biological activities related to T-cell functions. Fibrinogen-like protein 1 (FGL1) is a major LAG-3 functional ligand that is upregulated in various human cancers. LAG-3 positive T cells bind FGL1 expressed by cancer cells, which inhibits T-cell activation and cytokine secretion via indirect blocking of T cell receptor (TCR) signaling. High expression of LAG-3 and FGL1 in patients with solid tumors is associated with drug resistance and decreased survival in response to FDA-approved immune checkpoint inhibitors. Therefore, targeting the LAG-3/FGL1 pathway represents a promising therapeutic strategy to maximize the number of patients benefiting from checkpoint blockade therapy. However, there are no small molecules in existence that target LAG-3/FGL1 interaction. Herein, we report a time-resolved fluorescence resonance energy transfer (TR-FRET) assay to evaluate the ability of small molecules to inhibit LAG-3/FGL1 interaction. We further demonstrate the implementation of the developed assay in screening chemical libraries of small molecules from the NCI Diversity Set VII, FDA-approved drugs, and a focused library of NF-κB modulators. This work will pave the way for drug discovery efforts focused on therapeutic targeting of LAG-3/FGL1 interaction using small molecules.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorescence Resonance Energy TransferHigh-Throughput Screening AssaysHumansDrug DiscoverySmall Molecule LibrariesLymphocyte ActivationFibrinogen

Stichwörter der Autor:innen

Assay developmentCancer immunotherapyHigh-throughput screeningImmune checkpointsTR-FRET

Substanzen

Small Molecule LibrariesFGL1 protein, humanFibrinogen

Autor:innen und Institutionen

  • Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, NY 10065, USA; Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
  • Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, NY 10065, USA.
  • Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, NY 10065, USA. Electronic address: mog4005@med.cornell.edu.

Zitieren

APA

Abdel-Rahman, S. A., Zhang, L., & Gabr, M. T. (2023). Development of a high-throughput TR-FRET screening assay for LAG-3/FGL1 interaction. SLAS Discovery. https://doi.org/10.1016/j.slasd.2023.04.003

Vancouver

Abdel-Rahman SA, Zhang L, Gabr MT. Development of a high-throughput TR-FRET screening assay for LAG-3/FGL1 interaction. SLAS Discovery. 2023. doi:10.1016/j.slasd.2023.04.003

BibTeX
@article{AbdelRahman2023,
  author = {Abdel-Rahman, Somaya A and Zhang, Longfei and Gabr, Moustafa T},
  title = {Development of a high-throughput TR-FRET screening assay for LAG-3/FGL1 interaction},
  journal = {SLAS Discovery},
  year = {2023},
  doi = {10.1016/j.slasd.2023.04.003}
}
Kostenlos starten →